# A Study of PTS100 in Primary HCC Patients

> **NCT03447951** · PHASE2 · UNKNOWN · sponsor: **Gongwin Biopharm Co., Ltd.** · enrollment: 33 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Para-Toluenesulfonamide

## Key facts

- **NCT ID:** NCT03447951
- **Lead sponsor:** Gongwin Biopharm Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-06-19
- **Primary completion:** 2024-12
- **Final completion:** 2025-12
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2023-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03447951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03447951, "A Study of PTS100 in Primary HCC Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03447951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*